Compare Charles River Laboratories Intl. Inc (CRL) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs NetEase Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while NetEase Inc trades at $129.23 (market cap $82.39B). The key difference: NetEase Inc is far larger — about 7.4× Charles River Laboratories Intl. Inc's market cap, and NetEase Inc pays a 2.35% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | NTES | |
|---|---|---|
Market Cap | $11.14B | $82.39B |
Sector | Health | Media |
52-Week High | $233.60 | $159.34 |
52-Week Low | $145.57 | $109.26 |
Enterprise Value | $14.00B | $58.86B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
NTES trades at $131.43, up 2.66% today, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.84% net income margin and 22.12% ROE. Recent Q1 2026 earnings beat expectations at $2.53 EPS versus $2.19 forecast. Analyst sentiment is overwhelmingly positive with 82% buy ratings. Cash flow from operations surged to $50.74B in 2025, though net cash flow was negative due to heavy investing activities.
Outlook remains favorable given earnings momentum, international expansion in gaming, and attractive valuation at 16.89 P/E. Risks include reliance on Chinese market and competitive pressures. Wall Street sees 34.7% upside potential based on price targets, supporting a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
